Story

BlossomHill Therapeutics Shares Fall in Trading Debut After $150 Million IPO

ENTHMSVIIDZHZH-TWJAKOHI
Aug 7, 20261 min read
BlossomHill Therapeutics Shares Fall in Trading Debut After $150 Million IPO
Text size
Background

Shares of BlossomHill Therapeutics Inc. (NASDAQ: BLSM) declined in their public market debut on Friday, a day after the oncology-focused biotechnology firm raised $150 million in an upsized initial public offering. The stock's performance indicates a muted reception from investors for the newly listed company.

Market Performance

BlossomHill's stock opened for trading in New York at $15.75, below its IPO price of $16.00 per share. According to Investing.com, the shares ended their first session down 1.6%.

Based on the number of outstanding shares listed in its filings, the trading gives the San Diego-based clinical-stage biopharmaceutical company a market valuation of approximately $482.6 million.

Offering Details

Sample IUX Markets – In-articleAd

The company priced its IPO on Thursday, selling 9,375,000 shares of common stock. This was an increase from the 7.8 million shares it had initially marketed at a price range of $15 to $17 each.

The offering generated gross proceeds of $150 million, before deducting underwriting discounts and other expenses. The deal's underwriters have a 30-day option to purchase up to an additional 1,406,250 shares at the public offering price. The offering is expected to close on August 10, 2026, subject to customary closing conditions.

J.P. Morgan, Leerink Partners, and Guggenheim Securities acted as lead book-running managers for the offering, with LifeSci Capital and H.C. Wainwright & Co. serving as joint book-running managers.

Read next

More on Stocks
Back to latest news

LATEST